Literature DB >> 29392037

Laryngomalacia: Our Clinical Experience.

Yüksel Olgun1, Hüseyin Özay1, Aslı Çakır1, Taner Kemal Erdağ1.   

Abstract

OBJECTIVE: The aim of this study is to analyse the clinical symptoms, follow-up and treatment properties of the laryngomalacia patients that we encountered between 2009 and 2014.
METHODS: Records of 81 laryngomalacia patients who were followed up in our clinic between 2009 and 2014 were retrospectively analysed. Patients' gender, age, time of onset of the symptoms, chief complaints, other co-existing congenital laryngeal anomalies and treatment and follow-up properties were evaluated.
RESULTS: Of the 81 patients, 48 were male and 33 were female, and the mean age was 4.9 months. The average period of follow-up was 12.1 months. The chief complaints at the time of admission were stridor (100%) and episodic cyanosis with feeding (27.16%). Symptoms of 75 patients were resolved at an average of 8.2 months with conservative treatment. Three patients underwent supraglottoplasty. Tracheotomy and posterior cordotomy was performed for a patient with co-existing vocal cord paralysis. Additional tracheotomy was necessary for a patient with pulmonary co-morbidities and for another with co-existing subglottic stenosis.
CONCLUSION: Laryngomalacia is the most common cause of stridor in infants. The majority of laryngomalacia patients can be managed conservatively by close follow-up. For patients in whom respiratory and feeding problems persist or growth retardation develops, surgical treatment is performed. Tracheotomy may be necessary for a small group of patients with additional diseases.

Entities:  

Keywords:  Airway; laryngomalacia; stridor; supraglottoplasty

Year:  2016        PMID: 29392037      PMCID: PMC5782953          DOI: 10.5152/tao.2016.1852

Source DB:  PubMed          Journal:  Turk Arch Otorhinolaryngol        ISSN: 2667-7466


  18 in total

1.  Submucosal nerve hypertrophy in congenital laryngomalacia.

Authors:  Patrick D Munson; Ali G Saad; Siraj M El-Jamal; Yuemeng Dai; Charles M Bower; Gresham T Richter
Journal:  Laryngoscope       Date:  2011-01-13       Impact factor: 3.325

2.  Laryngomalacia: patient outcomes following aryepiglottoplasty at a tertiary care center.

Authors:  A Erim Pamuk; Nilda Süslü; R Onder Günaydın; Gamze Atay; Umut Akyol
Journal:  Turk J Pediatr       Date:  2013 Sep-Oct       Impact factor: 0.552

3.  Laryngomalacia and its treatment.

Authors:  D R Olney; J H Greinwald; R J Smith; N M Bauman
Journal:  Laryngoscope       Date:  1999-11       Impact factor: 3.325

Review 4.  Laryngomalacia: factors that influence disease severity and outcomes of management.

Authors:  Dana M Thompson
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2010-12       Impact factor: 2.064

Review 5.  Laryngomalacia: Review and Summary of Current Clinical Practice in 2015.

Authors:  Marc C Thorne; Susan L Garetz
Journal:  Paediatr Respir Rev       Date:  2015-02-28       Impact factor: 2.726

6.  Management of laryngomalacia in children with congenital syndrome: the role of supraglottoplasty.

Authors:  Anette Escher; Rudolf Probst; Claudine Gysin
Journal:  J Pediatr Surg       Date:  2014-07-11       Impact factor: 2.545

7.  Synchronous airway lesions in laryngomalacia.

Authors:  Eilon Krashin; Josef Ben-Ari; Chaim Springer; Ari Derowe; Avraham Avital; Yakov Sivan
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2008-03-04       Impact factor: 1.675

8.  Synchronous airway lesions and outcomes in infants with severe laryngomalacia requiring supraglottoplasty.

Authors:  James W Schroeder; Naveen D Bhandarkar; Lauren D Holinger
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-07

9.  Etiology of stridor in infants.

Authors:  Richard Zoumalan; John Maddalozzo; Lauren D Holinger
Journal:  Ann Otol Rhinol Laryngol       Date:  2007-05       Impact factor: 1.547

10.  Abnormal sensorimotor integrative function of the larynx in congenital laryngomalacia: a new theory of etiology.

Authors:  Dana Mara Thompson
Journal:  Laryngoscope       Date:  2007-06       Impact factor: 3.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.